Loading...
Loading...
ENSC| Name | Value |
|---|---|
| Revenues | 789.6K |
| Cost of Revenue | 1,796.0K |
| Gross Profit | -1,006.4K |
| Operating Expense | 2,561.2K |
| Operating I/L | -2,561.2K |
| Other Income/Expense | 369.4K |
| Interest Income | 1.5K |
| Pretax | -2,191.8K |
| Income Tax Expense | -363.6K |
| Net Income/Loss | -1,828.2K |
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing abuse-resistant opioid prodrugs for severe pain relief and overdose protection. The company's products include PF614, a TAAP prodrug candidate of oxycodone for acute and chronic pain treatment; PF614-MPAR, a combination product for overdose protection; PF329, an extended-release prodrug of hydromorphone; PF8001 and PF8026, extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder.
